[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371844-105":59,"doc-detail-371844-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pa2g4-functions-as-a-cofactor-for-myc-family-oncoproteins-in-myc-driven-malignancies","PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies","","MYCN and c-MYC act as central oncogenic drivers in multiple childhood cancers, including neuroblastoma. Clinical progress on MYC inhibition is limited by MYC’s intrinsically disordered nature and lack of defined ligand-binding pockets. This study shows that PA2G4 directly binds and stabilizes MYCN, promoting neuroblastoma tumor growth in vivo. It also increases c-MYC by blocking ubiquitin-mediated degradation, while c-MYC transcriptionally upregulates PA2G4, forming an oncogenic feed-forward loop. A PA2G4 inhibitor, WS6, disrupts the PA2G4–c-MYC protein interaction, reducing both proteins and exhibiting selective cytotoxicity in c-MYC-overexpressing models. These results position PA2G4 as a shared cofactor and a therapeutic vulnerability in MYC-driven malignancies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pa2g4-functions-as-a-cofactor-for-myc-family-oncoproteins-in-myc-driven-malignancies/371844/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pa2g4-functions-as-a-cofactor-for-myc-family-oncoproteins-in-myc-driven-malignancies/371844.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does PA2G4 play in MYCN-driven neuroblastoma?","Question",{"text":113,"@type":114},"PA2G4 directly binds to and stabilizes MYCN, leading to markedly increased MYCN levels and supporting neuroblastoma tumor growth in vivo.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does PA2G4 affect c-MYC protein levels?",{"text":118,"@type":114},"PA2G4 elevates c-MYC by inhibiting its ubiquitin-mediated degradation, increasing c-MYC protein levels in neuroblastoma cells.",{"name":120,"@type":111,"acceptedAnswer":121},"How does the PA2G4 inhibitor WS6 influence the PA2G4–c-MYC interaction and cancer cell survival?",{"text":122,"@type":114},"WS6 disrupts the PA2G4–c-MYC protein–protein interaction, decreasing levels of both PA2G4 and c-MYC and showing selective cytotoxicity in c-MYC-overexpressing cell lines.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},371844,1790236657,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nPA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies  \nSukriti Krishan 1,2, Jessica Koach 1,2, Taylor Lim 1,2, Kenny Yeo 1,2, Faith Cheong 1,2, Jie-Si Luo 1,2, Hassina Massudi 1,2, Xiaomian Gao 1,2, Sopheakwealthy Heangsarath 1,2, Andrew J. Kueh 3,4,5,6, Marco J. Herold 3,4,5,6, Belamy B. Cheung 1,2,* and Glenn M. Marshall 1,2,7,*  \nAcademic Editor: Edward V. Prochownik  \nReceived: 15 July 2025  \nRevised: 18 August 2025  \nAccepted: 8 September 2025  \nPublished: 11 September 2025  \nCitation: Krishan, S.; Koach, J.; Lim, T.; Yeo, K.; Cheong, F.; Luo, J.-S.; Massudi, H.; Gao, X.; Heangsarath, S.; Kueh, A.J.; et al. PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies. Cells 2025, 14, 1422. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cells14181422](10.3390/cells14181422)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales Sydney (UNSW), Sydney, NSW 2052, Australia; [skrishan@ccia.org.au](skrishan@ccia.org.au) (S.K.); [jessica.koach@arodia.com](jessica.koach@arodia.com) (J.K.); [xinyilim.06@gmail.com](xinyilim.06@gmail.com) (T.L.); [kyeo@ccia.org.au](kyeo@ccia.org.au) (K.Y.); [luojs5@mail.sysu.edu.cn](luojs5@mail.sysu.edu.cn) (J.-S.L.); [swealthysheang@gmail.com](swealthysheang@gmail.com) (S.H.)  \n2 School of Clinical Medicine, UNSW Medicine & Health, University of New South Wales Sydney (UNSW), Sydney, NSW 2052, Australia  \n3 Olivia Newton-John Cancer Research Institute, Heidelberg, Melbourne, VIC 3086, Australia; [andrew.kueh@onjcri.org.au](andrew.kueh@onjcri.org.au) (A.J.K.); [marco.herold@onjcri.org.au](marco.herold@onjcri.org.au) (M.J.H.)  \n4 School of Cancer Medicine, La Trobe University, Heidelberg, Melbourne, VIC 3000, Australia  \n5 The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC 3050, Australia  \n6 Department of Medical Biology, University of Melbourne, Parkville, Melbourne, VIC 3010, Australia  \n7 Kids Cancer Centre, Sydney Children’s Hospital, Randwick, Sydney, NSW 2031, Australia  \n* [Correspondence: bcheung@ccia.unsw.edu.au](Correspondence: bcheung@ccia.unsw.edu.au) (B.B.C.); [glenn.marshall@health.nsw.gov.au](glenn.marshall@health.nsw.gov.au) (G.M.M.); Tel.: +61-(02)-9385-2450 or +61-(02)-9382-1721 (B.B.C. & G.M.M.)  \nAbstract  \nMYCN and c-MYC are critical driver oncogenes in several childhood cancers, including neuroblastoma. Currently, the clinical development of MYC inhibitors has been hindered by the intrinsically disordered structure of MYC proteins, which lack well-defined ligand-binding pockets. Proliferation-associated protein 2G4 (PA2G4) directly binds to and stabilizes MYCN protein, leading to markedly increased MYCN levels in neuroblastoma cells. Here, we demonstrate that PA2G4 is essential for MYCN-driven tumor growth in neuroblastoma in vivo. Moreover, PA2G4 elevates c-MYC protein levels in neuroblastoma cells by inhibiting its ubiquitin-mediated degradation. In turn, c-MYC upregulates the transcription and protein expression of PA2G4, creating an oncogenic feed-forward expression loop. A small molecule PA2G4 inhibitor, WS6, directly disrupts the PA2G4-c-MYC protein–protein interaction, resulting in decreased levels of both PA2G4 and c-MYC. WS6 exhibited selective cytotoxicity in c-MYC-overexpressing cell lines. Together, these findings identify PA2G4 as a shared cofactor for both the c-MYC and MYCN oncoproteins and highlight its interaction with MYC family oncoproteins as a promising therapeutic vulnerability in MYC-driven cancers.  \nKeywords: MYC; MYCN; PA2G4; neuroblastom","cbCaitLBbS1OYYAv","https://ap.wps.com/l/cbCaitLBbS1OYYAv","pdf",2044293,15,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What role does PA2G4 play in MYCN-driven neuroblastoma?\",\"answer\":\"PA2G4 directly binds to and stabilizes MYCN, leading to markedly increased MYCN levels and supporting neuroblastoma tumor growth in vivo.\"},{\"question\":\"How does PA2G4 affect c-MYC protein levels?\",\"answer\":\"PA2G4 elevates c-MYC by inhibiting its ubiquitin-mediated degradation, increasing c-MYC protein levels in neuroblastoma cells.\"},{\"question\":\"How does the PA2G4 inhibitor WS6 influence the PA2G4–c-MYC interaction and cancer cell survival?\",\"answer\":\"WS6 disrupts the PA2G4–c-MYC protein–protein interaction, decreasing levels of both PA2G4 and c-MYC and showing selective cytotoxicity in c-MYC-overexpressing cell lines.\"}]","PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies | PDF",1790193007,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c7ed1780df19bbe01bbe8dde58a94af.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb004ff1be025f9f877ae1207aa13b4d.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16267a2ee13d6d6d4ec7f34019f48ab0.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb87c4b63d3e5bc9d43b2f1fc97e793f.webp",980,1385]